BTG3 and systemic sclerosis: In addition, the prevalence of systemic autoantibodies was assessed for RF, ANA, and, in case of positive ANA, anti-ENA autoantibodies, a subset of ANA used to diagnose, differentiate, and monitor various autoimmune disorders and associated with different CTDs, including SLE, Sjögren’s syndrome, and different forms of systemic sclerosis (23).